SCHEMBL5126940

SCHEMBL5126940

NC(=O)C=C1NCCc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.51
PARP1 P09874 1/20 0.51
PARP10 Q53GL7 1/20 0.51
PARP11 Q9NR21 1/20 0.51
KMT2A Q03164 3/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39
TUBA1C Q9BQE3 1/20 0.39
TUBB6 Q9BUF5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6485267 0.85 PDPK1 (0.53) PDPK1PARP1PARP10PARP11KMT2A
SCHEMBL6485264 0.85 PDPK1 (0.53) PDPK1PARP1PARP10PARP11KMT2A
SCHEMBL6485271 0.85 PDPK1 (0.53) PDPK1PARP1PARP10PARP11KMT2A
SCHEMBL14279596 0.80 PDPK1 (0.47) PDPK1PARP1PARP10PARP11KMT2A
SCHEMBL2552644 0.74 PARP10 (0.56) PDPK1PARP1PARP10PARP11TUBB4A
SCHEMBL9391477 0.74 CES1 (0.45) HTTNOTUMSMN1; SMN2CES1SRD5A1
SCHEMBL9391470 0.74 CES1 (0.45) HTTNOTUMSMN1; SMN2CES1SRD5A1
SCHEMBL9391471 0.74 CES1 (0.45) HTTNOTUMSMN1; SMN2CES1SRD5A1
SCHEMBL13808059 0.72 MAPT (0.71) KMT2AMEN1LMNAHTTSMN1; SMN2
SCHEMBL8780459 0.71 RXRA (0.56) KMT2AMEN1LMNANOTUMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120302533-A1 DERIVATIVES OF PYRIMIDO [6,1-A] ISOQUINOLIN-4-ONE VERONA PHARMA PLC (GB) 2012-11-29 US disclosed
US-8242127-B2 INHIBITORS OF PHOSPHODIESTERASE (PDE) ISOENZYMES; USEFUL FOR TREATMENT OF RESPIRATORY DISORDERS SUCH AS ASTHMA; chronic obstructive pulmonary disease (COPD); 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one VERONA PHARMA PLC (GB) 2012-08-14 US disclosed
US-20080206163-A1 Derivatives of pyrimido[6, 1-A]isoquinolin-4-one VERONA PHARMA PLC (GB) 2008-08-28 US disclosed
US-7378424-B2 Derivatives of pyrimido[6, 1-A]isoquinolin-4-one VERONA PHARMA PLC (GB) 2008-05-27 US disclosed
US-7105663-B2 Derivatives of pyrimido[6,1-a]isoquinolin-4-one RHINOPHARMA LIMITED (CA) 2006-09-12 US disclosed
US-6794391-B2 INHIBITORS OF PHOSPHODIESTERASE (PDE) ISOENZYMES; USEFUL FOR TREATMENT OF RESPIRATORY DISORDERS SUCH AS ASTHMA. VERNALIS LIMITED (GB) 2004-09-21 US disclosed
US-20040176353-A1 Derivatives of pyrimido[6,1-a]isoquinolin-4-one VERNALIS LIMITED 2004-09-09 US disclosed
US-20040171828-A1 Derivatives of pyrimido[6,1-a]isoquinolin-4-one VERNALIS LIMITED 2004-09-02 US disclosed
EP-1165558-B1 DERIVATIVES OF PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE VERNALIS LTD (GB) 2003-09-24 EP disclosed
US-20030036542-A1 Derivatives of pyrimido[6.1-a]isoquinolin-4-one VERONA PHARMA PLC (GB) 2003-02-20 US disclosed
EP-1165558-A1 DERIVATIVES OF PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE Vernalis Limited (GB) 2002-01-02 EP disclosed
EP-1165556-A1 DERIVATIVES OF PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE Vernalis Limited (GB) 2002-01-02 EP disclosed
WO-2000058309-A1 DERIVATIVES OF PYRIMIDO[6,1-A]ISOQUINOLIN-4-ONE VERNALIS LIMITED (GB) 2000-10-05 WO disclosed
WO-2000058308-A1 DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE VERNALIS LIMITED (GB) 2000-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302533-A1 DERIVATIVES OF PYRIMIDO [6,1-A] ISOQUINOLIN-4-ONE PDE4A, PDE2A, PDE12 PDPK1 998/4885PARP1 277/4885PARP10 869/4885
US-20030036542-A1 Derivatives of pyrimido[6.1-a]isoquinolin-4-one CXCR6, HRH1, HRH2 PDPK1 4111/4885PARP1 934/4885PARP10 1607/4885
US-20040176353-A1 Derivatives of pyrimido[6,1-a]isoquinolin-4-one TAS1R2, TAS2R1, TAS2R7 PDPK1 3557/4885PARP1 1487/4885PARP10 1960/4885
US-20040171828-A1 Derivatives of pyrimido[6,1-a]isoquinolin-4-one TAS2R1, TAS2R7, TAS2R50 PDPK1 3913/4885PARP1 1716/4885PARP10 2059/4885
US-20080206163-A1 Derivatives of pyrimido[6, 1-A]isoquinolin-4-one HRH2, HRH4, TAS2R3 PDPK1 4279/4885PARP1 2579/4885PARP10 1409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.